Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30596052 | 1.00 | IRAK4 (0.53) | IRAK4XDH | |
| SCHEMBL17137729 | 0.86 | IRAK4 (0.41) | IRAK4XDH | |
| SCHEMBL17136997 | 0.85 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL30497336 | 0.85 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL18553871 | 0.84 | IRAK4 (0.53) | IRAK4XDH | |
| SCHEMBL17137104 | 0.82 | IRAK4 (0.40) | IRAK4 | |
| SCHEMBL17137611 | 0.82 | TDP1 (0.42) | IRAK4XDH | |
| SCHEMBL17136869 | 0.81 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL17137683 | 0.81 | IRAK4 (0.37) | IRAK4XDH | |
| SCHEMBL17137481 | 0.79 | SRC (0.43) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459941-B2 | Tricyclic IRAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230312568-A1 | TRICYCLIC IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312568-A1 | TRICYCLIC IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192479-A1 | TRICYCLIC IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192479-A1 | TRICYCLIC IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015150995-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150995-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312568-A1 | TRICYCLIC IRAK INHIBITORS | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885XDH 2516/4885 |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885XDH 85/4885 |
| US-12459941-B2 | Tricyclic IRAK inhibitors | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885XDH 2516/4885 |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885XDH 85/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | IRAK4 1318/4885XDH 188/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | IRAK4 1318/4885XDH 188/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885XDH 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.